Letters to the Editor Open access

Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction

Authors

Published
29 May 2023
Section
Letters to the Editor
DOI
10.4081/aiua.2023.11350

Abstract

To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples’ relationship, and quality of life. [...]

Keywords

References

  1. Attia AA, Abdel-Hameed AKS, Amer MAEM, et al. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: A National Cross-sectional Survey. Andrologia. 2019; 51:e13364. DOI: https://doi.org/10.1111/and.13364
  2. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T. 2013; 38:407-19.
  3. Atsbeha BW, Kebede BT, Birhanu BS, et al. The Weekend Drug; Recreational Use of Sildenafil Citrate and Concomitant Factors: A Cross-Sectional Study. Front Med (Lausanne). 2021; 8:665247. DOI: https://doi.org/10.3389/fmed.2021.665247
  4. Mulhall JP, Hassan TA, Rienow J. Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries. Int J Clin Pract. 2018; 72:e13074. DOI: https://doi.org/10.1111/ijcp.13074
  5. Cirillo L, Fusco GM, Di Bello F, et al. Sexual dysfunction: Time for a multidisciplinary approach? Arch Ital Urol Androl. 2023; 95:11236. DOI: https://doi.org/10.4081/aiua.2023.11236
  6. Bechara A, Casabé A, De Bonis W, et al. Recreational Use of Phosphodiesterase Type 5 Inhibitors by Healthy Young Men. J Sex Med. 2010;7:3736-42. DOI: https://doi.org/10.1111/j.1743-6109.2010.01965.x
  7. Korkes F, Costa-Matos A, Gasperini R, et al. Recreational Use of PDE5 Inhibitors by Young Healthy Men: Recognizing This Issue Among Medical Students. J Sex Med. 2008; 5:2414-2418. DOI: https://doi.org/10.1111/j.1743-6109.2008.00792.x
  8. Kimura M, Shimura S, Kobayashi H, et al. Profiling Characteristics of Men Who Use Phosphodiesterase Type 5 Inhibitors Based on Obtaining Patterns: Data from the Nationwide Japanese Population. J Sex Med 2012; 9:1649-1658. DOI: https://doi.org/10.1111/j.1743-6109.2012.02728.x
  9. Alshahrani S, Ahmed AF, Gabr AH, Al Ansari A, El-feky M, Elbadry MS. Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia. Arab Journal of Urology. 2016; 14:94-100. DOI: https://doi.org/10.1016/j.aju.2016.03.003
  10. Mirone V, Napolitano L, D’Emmanuele di Villa Bianca R, et al. A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. Arch Ital Urol Androl. 2021; 93:221-226. DOI: https://doi.org/10.4081/aiua.2021.2.221
  11. Ahmed AF, Alshahrani S, Morgan A, et al. Demographics and sexual characteristics of sex-enhancing medication users: Study of a web-based cross-sectional sample of sexually active men. Arab Journal of Urology. 2017; 15:366-371. DOI: https://doi.org/10.1016/j.aju.2017.09.003
  12. Napolitano L, Fusco GM, Cirillo L, et al. Erectile dysfunction and mobile phone applications: Quality, content and adherence to European Association guidelines on male sexual dysfunction. Arch Ital Urol Androl. 2022; 94:211-216. DOI: https://doi.org/10.4081/aiua.2022.2.211
  13. Schnetzler G, Banks I, Kirby M, et al. Original Research—ED Pharmacotherapy: Characteristics, Behaviors, and Attitudes of Men Bypassing the Healthcare System When Obtaining Phosphodiesterase Type 5 Inhibitors. J Sex Med 2010; 7:1237-1246. DOI: https://doi.org/10.1111/j.1743-6109.2009.01674.x
  14. Harte CB, Meston CM. Recreational Use of Erectile Dysfunction Medications and Its Adverse Effects on Erectile Function in Young Healthy Men: The Mediating Role of Confidence in Erectile Ability. J Sex Med 2012; 9:1852-1859. DOI: https://doi.org/10.1111/j.1743-6109.2012.02755.x
  15. Napolitano L, Cirillo L, Fusco GM, et al. Natural treatments for erectile dysfunction: A focus on mobile health applications. Arch Ital Urol Androl. 2022; 94:373-374. DOI: https://doi.org/10.4081/aiua.2022.3.373

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2023 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.